Ann Strydom

发表

Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients

S. Seal, N. Rahman, M. Gore, 2016, Scientific Reports.

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer

N. Rahman, A. George, Ann Strydom, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

A discrete event simulation to evaluate the cost effectiveness of germline BRCA1 and BRCA2 testing in UK women with ovarian cancer

N. Rahman, A. George, Ann Strydom, 2016, bioRxiv.

A discrete event simulation to evaluate the cost effectiveness of germline BRCA 1 and BRCA 2 testing in UK women with ovarian cancer

N. Rahman, A. George, Ann Strydom, 2016 .

A discrete event simulation model was developed that included the risks of breast and ovarian cancer, the costs, utilities and effects of risk-reducing surgery on cancer rates, and the costs, utilities and mortality rates associated with cancer.

N. Rahman, Ann Strydom, M. Dyer, 2016 .

The ICR142 NGS validation series: a resource for orthogonal assessment of NGS analysis

S. Seal, N. Rahman, A. Renwick, 2016, F1000Research.

The ICR142 NGS validation series: a resource for orthogonal assessment of NGS analysis

S. Seal, N. Rahman, A. Renwick, 2018, F1000Research.

The ICR 142 NGS validation series : a resource for orthogonal assessment of NGS analysis [ version 1 ; referees : awaiting peer review ]

S. Seal, N. Rahman, A. Renwick, 2016 .

A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland

S. Seal, N. Rahman, M. Kerin, 2022, Familial Cancer.

CoverView: a sequence quality evaluation tool for next generation sequencing data

S. Seal, N. Rahman, S. Mahamdallie, 2018, Wellcome open research.

The ICR639 CPG NGS validation series: A resource to assess analytical sensitivity of cancer predisposition gene testing

Shazia Mahamdallie, Elise Ruark, Anthony Renwick, 2018, Wellcome open research.

Accurate clinical detection of exon copy number variants in a targeted NGS panel using DECoN

Nazneen Rahman, Anna Fowler, Gerton Lunter, 2016, Wellcome open research.

Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer

Nazneen Rahman, Shazia Mahamdallie, Shawn Yost, 2019, JAMA network open.

A cost analysis of a cancer genetic service model in the UK

N. Rahman, I. Slade, H. Hanson, 2015, bioRxiv.

CSN and CAVA: variant annotation tools for rapid, robust next-generation sequencing analysis in the clinical setting

Nazneen Rahman, Gerton Lunter, Shazia Mahamdallie, 2015, Genome Medicine.

The ICR96 exon CNV validation series: a resource for orthogonal assessment of exon CNV calling in NGS data

S. Seal, N. Rahman, A. Renwick, 2017, Wellcome Open Research.

CSN and CAVA: variant annotation tools for rapid, robust next-generation sequencing analysis in the clinical setting

S. Seal, N. Rahman, G. Lunter, 2015, Genome Medicine.

The ICR1000 UK exome series: a resource of gene variation in an outbred population

S. Seal, N. Rahman, A. Renwick, 2015, F1000Research.

The ICR142 NGS validation series: a resource for orthogonal assessment of NGS analysis

S. Seal, N. Rahman, A. Renwick, 2016, F1000Research.

The Quality Sequencing Minimum (QSM): providing comprehensive, consistent, transparent next generation sequencing data quality assurance

Shazia Mahamdallie, Elise Ruark, Shawn Yost, 2018, Wellcome open research.

The Quality Sequencing Minimum (QSM): providing comprehensive, consistent, transparent next generation sequencing data quality assurance [version 1; peer review: 2 approved, 1 approved with reservations]

S. Seal, N. Rahman, A. Renwick, 2021 .